Quick Answer
Mirum Pharmaceuticals, Inc. reported Diluted EPS of $0.47 per share (loss) for fiscal year 2025.
Mirum Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.47 | +74.6% |
| 2024 | -$1.85 | +53.8% |
| 2023 | -$4.00 | +0.5% |
| 2022 | -$4.02 | -45.1% |
| 2021 | -$2.77 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.05 | +116.7% | +141.7% |
| June 30, 2025 | -$0.12 | +76.9% | +60.0% |
| March 31, 2025 | -$0.30 | +44.4% | +0.0% |
| September 30, 2024 | -$0.30 | +47.4% | +42.3% |
| June 30, 2024 | -$0.52 | +73.2% | +3.7% |
| March 31, 2024 | -$0.54 | +32.5% | +5.3% |
| September 30, 2023 | -$0.57 | +44.1% | +70.6% |
| June 30, 2023 | -$1.94 | -131.0% | -142.5% |
- Mirum Pharmaceuticals, Inc. showed an increase of +74.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Mirum Pharmaceuticals, Inc.’s diluted eps has grown by 83.0% (from $2.77 per share (loss) to $0.47 per share (loss)).
- The most recent figure is from Mirum Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: